A Randomized and Controlled Ⅳ Clinical Trial to Evaluate the Immunogenicity and Safety of COVID-19 Vaccine (Vero Cell), Inactivated Co-administrated With EV71 Vaccine (Vero Cell) in Children Aged 3-5 Years Old
Latest Information Update: 12 Oct 2023
At a glance
- Drugs Influenza-virus-vaccine-quadrivalent-Sinovac-Biotech (Primary) ; Pneumococcal 23 valent vaccine Sinovac Biotech (Primary) ; SARS-COV-2 vaccine-inactivated-Sinovac-Biotech (Primary)
- Indications COVID 2019 infections
- Focus Pharmacodynamics
- Sponsors Sinovac Biotech
- 07 Oct 2023 Status changed from suspended to completed.
- 09 Aug 2022 Planned number of patients changed from 1320 to 520.
- 09 Aug 2022 Planned End Date changed from 1 Aug 2022 to 1 Jul 2023.